TriSalus Life Sciences, Inc.
NGM: TLSILive Quote
📈 ZcoreAI Score
Our AI model analyzes TriSalus Life Sciences, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get TLSI Z-Score →About TriSalus Life Sciences, Inc.
Healthcare
Medical Devices
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.
📊 Fundamental Analysis
TriSalus Life Sciences, Inc. demonstrates a profit margin of -86.9%, which is below the sector average, suggesting competitive pressure.
The company recently reported 59.8% revenue growth, which is well above average for the Healthcare sector.
At a current price of $4.22, TLSI currently trades near the bottom of its 52-week range (18%), indicating potential value or weakness (Range: $3.42 - $7.95).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Revenue Growth
Excellent
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$259.17M
Trailing P/E
--
Forward P/E
-16.88
Beta (5Y)
0.54
52W High
$7.95
52W Low
$3.42
Avg Volume
185K
Day High
Day Low